Barbara A. Crothers

Barbara A. Crothers

Auto-generated profile, based on publicly available information

Barbara A. Crothers

Joint Pathology Center, Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 March 2018 in Cancer Cytopathology
Verified
Journal Article
Open access
PDF file
BCBarbara A. Crothers
Barbara A. Crothers
The author was the chair of a College of American Pathologists working group at the Gynecologic Cytopathology Quality Consensus Conference outlining then current practices in cytology‐histology correlation, and published this work in the Archives of Pathology and Laboratory Medicine. Cancer Cytopathol 2018;126:301‐8. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

10 March 2022 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
LNLananh N. Nguyen
Lananh N. Nguyen
BCBarbara A. Crothers
Barbara A. Crothers
DDDiane Davey
Diane Davey
KNKristen E. Natale
Kristen E. Natale
ANAmberly L. Nunez
Amberly L. Nunez
CBChristine N. Booth
Christine N. Booth
Context.—: The College of American Pathologists (CAP) updated the Laboratory Accreditation Program Cytopathology Checklist to assist laboratories in meeting and exceeding the Clinical Laboratory Improvement Amendments standards for gynecologic cytologic-histologic correlation (CHC). Objective.—: To survey the current CHC practices. Design.—: Data were analyzed from a survey developed by the committee and distributed to participants in the CAP Gynecologic Cytopathology PAP Education Program mailing. Results.—: Worldwide, CHC practice is nearly universally adopted, with an overall rate of 87.0% (568 of 653). CHC material was highly accessible. CHC was commonly performed real time/concurrently at the time the corresponding surgical pathology was reviewed. Investigation of CHC discordances varied with North American laboratories usually having a single pathologist review all discrepant histology and cytology slides to determine the reason for discordance, while international laboratories have a second pathologist review histology slides to determine the reason for discordance. The cause of CHC discordance was primarily sampling issues. The more common statistical metrics for CHC monitoring were the total percentage of cases that correlated with subsequent biopsies, screening error rate by cytotechnologist, and interpretative error rate by cytotechnologist. Conclusions.—: Many laboratories have adopted and implemented the CHC guidelines with identifiable differences in practices between North American and international laboratories. We identify the commonalities and differences between North American and international institutional practices including where CHC is performed, how CHC cases are identified and their accessibility, when CHC is performed, who investigates discordances, what discordances are identified, and how the findings affect quality improvement.

22 August 2018 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
BCBarbara A. Crothers
Barbara A. Crothers
MGMohiedean Ghofrani
Mohiedean Ghofrani
CZChengquan Zhao
Chengquan Zhao
LDLeslie G. Dodd
Leslie G. Dodd
KGKelly Goodrich
Kelly Goodrich
DDDiane Davis Davey
Diane Davis Davey
Context.—: Obtaining diagnostic concordance for squamous intraepithelial lesions in cytology can be challenging. Objective.—: To determine diagnostic concordance for biopsy-proven low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL) Papanicolaou test slides in the College of American Pathologists PAP Education program. Design.—: We analyzed 121 059 responses from 4251 LSIL and HSIL slides for the interval 2004 to 2013 using a nonlinear mixed-model fit for reference diagnosis, preparation type, and participant type. We evaluated interactions between the reference diagnosis and the other 2 factors in addition to a repeated-measures component to adjust for slide-specific performance. Results.—: There was a statistically significant difference between misclassification of LSIL (2.4%; 1384 of 57 664) and HSIL (4.4%; 2762 of 63 395). There was no performance difference between pathologists and cytotechnologists for LSIL, but cytotechnologists had a significantly higher HSIL misclassification rate than pathologists (5.5%; 1437 of 27 534 versus 4.0%; 1032 of 25 630; P = .01), and both were more likely to misrepresent HSIL as LSIL (P < .001) than the reverse. ThinPrep LSIL slides were more likely to be misclassified as HSIL (2.4%; 920 of 38 582) than SurePath LSIL slides (1.5%; 198 of 13 196), but conventional slides were the most likely to be misclassified in both categories (4.5%; 266 of 5886 for LSIL, and 6.5%; 573 of 8825 for HSIL). Conclusions.—: More participants undercalled HSIL as LSIL (false-negative) than overcalled LSIL as HSIL (false-positive) in the PAP Education program, with conventional slides more likely to be misclassified than ThinPrep or SurePath slides. Pathologists and cytotechnologists classify LSIL equally well, but cytotechnologists are significantly more likely to undercall HSIL as LSIL than are pathologists.

3 May 2025 in Cancer Cytopathology
Verified
Journal Article
Open access
WYWei‐Lei Yang
Wei‐Lei Yang
BCBarbara A. Crothers
Barbara A. Crothers
TLTien‐Jen Liu
Tien‐Jen Liu
SHShih‐Wen Hsu
Shih‐Wen Hsu
CYCheng‐Hung Yeh
Cheng‐Hung Yeh
JHJen-Fan Hang
Jen-Fan Hang
Background: The Paris System (TPS) introduced standardized nuclear‐to‐cytoplasmic (N/C) ratio thresholds for urine cytology to improve high‐grade urothelial carcinoma (HGUC) detection, but these criteria remain subjective. This study used AIxURO, an artificial intelligence‐based model, to measure N/C ratio and nuclear area to identify abnormal cells in whole slide images (WSIs).Methods: A total of 106 urine cytology slides from 46 lower urinary tract (LUT) and 60 upper urinary tract (UUT) cancer cases, diagnosed as atypical urothelial cell (15.1%), suspicious for high‐grade urothelial carcinoma (SHGUC) (23.6%), and HGUC (61.3%), with biopsy‐confirmed HGUC or carcinoma in situ (CIS), were digitized and analyzed by AIxURO. The model quantified suspicious and atypical cells, N/C ratios, and nuclear areas, with statistical differences assessed using Kruskal–Wallis tests.Results: AIxURO identified fewer suspicious cells than atypical cells (20.5 vs. 242.0, p < .001). Suspicious cells had higher N/C ratios (0.66 vs. 0.58, p < .001) and larger nuclear areas (102.3 vs. 85.7 µm2, p < .001). Although N/C ratios did not differ significantly between UUT and LUT cases, nuclear areas varied among abnormal cells (CIS: 101.5 µm2; HGUC: 83.5 µm2). In HGUC cytology cases, the CIS category had larger nuclear areas than HGUC for both suspicious (116.3 vs. 100.4 µm2) and atypical cells (101.5 vs. 82.2 µm2).Conclusions: AIxURO provides objective quantification of N/C ratios and nuclear areas, refining TPS criteria for distinguishing suspicious from atypical cells. A lower N/C ratio cutoff (0.66) for SHGUC/HGUC may be more appropriate than the TPS threshold (>0.7). Findings support using consistent N/C ratio criteria across UUT and LUT cases.

6 November 2020
Verified
Book Chapter
Closed access
PDF file
BCBarbara Crothers
Barbara Crothers
ZBZubair Baloch
Zubair Baloch
ACAshish Chandra
Ashish Chandra
SFSahar Farahani
Sahar Farahani
DKDaniel Kurtycz
Daniel Kurtycz
FSFernando Schmitt
Fernando Schmitt